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A B S T R A C T
Purpose
Disparities in receipt of adjuvant chemotherapy may contribute to higher breast cancer fatality
rates among black and Hispanic women compared with non-Hispanic whites. We investigated
factors associated with receipt of chemotherapy in a diverse population-based sample.
Patients and Methods
Women diagnosed with breast cancer between August 2005 and May 2007 (N  3,252) and
reported to the Detroit, Michigan, or Los Angeles County Surveillance, Epidemiology, and End
Results (SEER) registry were recruited to complete a survey. Multivariable analyses examined
factors associated with chemotherapy receipt.
Results
The survey was sent to 3,133 patients; 2,290 completed a survey (73.1%), and 1,403 of these
patients were included in the analytic sample. In multivariable models, disease characteristics
were significantly associated with the likelihood of receiving chemotherapy. Low-acculturated
Hispanics were more likely to receive chemotherapy than non-Hispanic whites (odds ratio [OR],
2.00; 95% CI, 1.31 to 3.04), as were high-acculturated Hispanics (OR, 1.43; 95% CI, 1.03 to 1.98).
Black women were less likely to receive chemotherapy than non-Hispanic whites, but the
difference was not significant (OR, 0.83; 95% CI, 0.64 to 1.08). Increasing age (even in women
age  50 years) and Medicaid insurance were associated with lower rates of chemothera-
py receipt.
Conclusion
In this population-based sample, disease characteristics were strongly associated with receipt of
chemotherapy, indicating that clinical benefit guides most treatment decisions. We found no
compelling evidence that black women and Hispanics receive chemotherapy at lower rates.
Interventions that address chemotherapy use rates according to age and insurance status may
improve quality of systemic treatment.
J Clin Oncol 30:3058-3064. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Breast cancer fatality rates in the United States
are higher among black and Hispanic women
than among non-Hispanic whites.1-4 Differences in
outcomes have been attributed to more advanced
stage and a higher likelihood of unfavorable tumor
biology features, such as hormone receptor–
negative disease and high-grade histology, among
black women and Hispanics compared with non-
Hispanic whites.5-26 Lower average socioeconomic
status (SES) among black women has been shown
to account in part for the racial disparity in
outcome.6,27-32 There is no corresponding informa-
tion on Hispanics, but higher rates of poverty and
lower rates of health insurance among Hispanics are
likely to contribute to poorer outcomes compared
with non-Hispanic whites.33 In particular, Hispan-
ics with limited English proficiency face additional
barriers to high-quality cancer information, deci-
sion support, and cancer care.34-37
Differences in the use of adjuvant chemo-
therapy have been proposed as another—and per-
haps substantial—explanation for the outcome
disparity among black women.38 Studies of chemo-
therapy use among black women have yielded
mixed results, with some studies reporting lower
rates of chemotherapy among black women,8,16,39-41
and others demonstrating that blacks are at least as
likely as whites to be administered chemothera-
py.18,42-44 The inconsistent findings most likely arise
from differences in patient sampling (hospital- or
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clinic-based patient samples v population-based samples), method of
assessing receipt versus nonreceipt of chemotherapy (registry data,
claims data, medical record review, patient self-report), and time
period and region under study. In contrast to the extensive research on
patterns of care in blacks, population-based studies of chemotherapy
receipt among Hispanics are extremely limited. Only one population-
based study with a large number of Hispanics has been published; this
study identified no evidence of undertreatment of Hispanics.45
Another study of patients treated in the clinical setting of six
hospitals in New York City demonstrated underuse of chemother-
apy among Hispanics,39 but other investigators employing clinical
samples46 or the National Cancer Database47 have not shown un-
deruse. Measures of acculturation, such as language preference,
have not been included in any of the studies examining chemother-
apy use rates among Hispanics.
Determining whether differences in chemotherapy receipt repre-
sent unwarranted disparities in chemotherapy is complicated. The
higher prevalence of stages II and III disease and of unfavorable histo-
logic features among blacks and Hispanics would increase the benefit
of chemotherapy. On the other hand, the higher prevalence of comor-
bid illness, such as cardiovascular disease and diabetes among
blacks48,49 and diabetes among Hispanics,50,51 could account for
what is actually appropriate omission of chemotherapy, because
competing causes of mortality decrease the marginal benefit of
chemotherapy.52,53 In addition, nonclinical characteristics, such as
insurance status54 and marital status,55,56 which vary among racial
and ethnic groups, have been associated with chemotherapy treat-
ment patterns and could contribute to relative underuse of chem-
otherapy among minority women.
This study was designed to address gaps in the literature regard-
ing the clinical and nonclinical factors associated with adjuvant chem-
otherapy receipt. We hypothesized that black and Hispanics women
would be less likely to receive adjuvant chemotherapy than non-
Hispanic whites after controlling for clinical and tumor characteris-
tics. We were particularly interested in the role of acculturation and
hypothesized that Hispanics who had low levels of acculturation
would be at highest risk for omission of adjuvant chemotherapy. This
hypothesis was informed by the work of other investigators who have
demonstrated disparities in access to health care among Hispanics
whose language preference is Spanish.34,35,57 In addition, we hypoth-
esized that nonclinical factors, including SES (education, income,
insurance status, employment status) and marital status, would con-
tribute to racial and ethnic disparities in receipt of chemotherapy.
Finally, we sought to characterize patient-reported reasons for nonre-
ceipt of chemotherapy.
PATIENTS AND METHODS
Study Sample and Data Collection
Our sample included women age 20 to 79 years diagnosed with Ameri-
can Joint Committee on Cancer stages I to III breast cancer or ductal carci-
noma in situ (DCIS) between June 2005 and May 2007 and reported to the
Surveillance, Epidemiology and End Results (SEER) tumor registry in Los
Angeles County or the tricounty metropolitan Detroit catchment area. For this
analysis, we excluded patients with DCIS (n  458), because chemotherapy is
not used in the treatment of noninvasive disease.
We recruited all eligible Hispanics in Los Angeles and all blacks in Los
Angeles and Detroit, in addition to a random sample of non-Hispanic
whites. Asian women were not included, because they were being recruited
by another investigator in Los Angeles, and the California Cancer Registry
requires extensive coordination of patient recruitment between research
groups when patients are being recruited to the studies of more than
one investigator.
After physician notification of our intention to contact their patients,
eligible patients were mailed a recruitment letter, survey, and $10 cash gift.
Patients who were likely to be Hispanic using a surname-based algorithm
described previously58 were mailed survey materials in English and Spanish.
The modified Dillman method was used to maximize survey response. The
Dillman method involves multiple methods of follow-up including postcard
reminders, second mailing of questionnaires, and telephone calls.59 Survey
responses were then merged with demographic and clinical data from the
SEER registries. The institutional review boards of the University of Michigan,
University of Southern California, and Wayne State University approved all
study procedures.
Measures
The dependent variable was patient report of receipt of chemotherapy.
Patient self-report of chemotherapy has been shown to be highly accurate and
valid when compared with medical record review60-62 and superior to data
from cancer registries.63 Independent variables included clinical characteris-
tics (age and comorbid conditions, both obtained from the patient survey),
disease characteristics obtained from SEER (American Joint Committee on
Cancer stage, estrogen receptor and progesterone receptor status, and
histologic grade), and nonclinical factors obtained from the patient survey
(race/ethnicity, educational attainment, insurance status, marital status,
employment status, and income). For patients with missing income infor-
mation, we assigned a value of “missing” and included the patients with
missing income (but otherwise complete information) in the analyses. The
SEER registries were not collecting information on human epidermal
growth factor receptor 2 (HER2) status during the recruitment period of
this study.
Acculturation in Hispanics was measured using the Short Acculturation
Scale for Hispanics (SASH),64,65 a validated measure of acculturation in His-
panic populations.66,67 The SASH includes five questions based on the respon-
dent’s language preference, each of which is answered on a 5-point scale from
1 (only English) to 5 (only Spanish). Responses to the SASH were dichoto-
mized into low (4 or 5) versus high acculturation (1, 2, or 3). Our previous
work evaluated the performance of the SASH by comparing it with other
measures of acculturation, including the number of years the respondent has
lived in the United States and the countries of origin of the respondent’s
mother and father.58
Patient race/ethnicity was then categorized into four groups: black, His-
panic with low acculturation, Hispanic with high acculturation, and non-
Hispanic white. Respondents who did not receive chemotherapy were asked to
select reasons from a list and could enter free text. Respondents could select
more than one reason. Patients for whom any of the covariates were missing
were excluded from the model, with the exception of income.
Statistical Analyses
Multivariable logistic regression analyses of chemotherapy receipt
included all clinical and nonclinical factors as independent variables. We
also controlled for registry (Detroit v Los Angeles). Population weights
were included in the multivariable analyses to account for differential
selection by race, ethnicity, and nonresponse. For patients with missing
income information, we assigned a value of “missing” and included the 243
patients (17%) with missing income (but otherwise complete informa-
tion) in the analyses. We did so because excluding these patients would
reduce power and generalizability with regard to our focus on race/ethnic-
ity and chemotherapy use. We tested for all two-way interactions; none
significantly affected the main results we present here, and they are not
included in the model.
Reasons for not receiving chemotherapy were tabulated under physician
related or patient related. These results were then tabulated to present the
Receipt of Breast Cancer Adjuvant Chemotherapy
www.jco.org © 2012 by American Society of Clinical Oncology 3059
141.211.191.66
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITY MICHIGAN on October 9, 2012 from
Copyright © 2012 American Society of Clinical Oncology. All rights reserved.
frequency with which each reason was reported; reasons for not receiving
chemotherapy were compared by race/ethnicity.
All statistical tests were two sided, and a P value less than .05 was consid-
ered statistically significant for bivariate and multivariate analyses. All analyses
were performed using SAS software (SAS Institute, Cary, NC).
RESULTS
The original sample selected from the SEER registries included
3,252 patients. After physician and patient contact, 119 were ex-
cluded (Fig 1). Of the remaining patients, 2,290 (73.1%) returned a
survey. After exclusions, most of which were because of a diagnosis
of DCIS (n  458) and missing information for any of the covari-
ates (n  305; range of missing covariates, 0% to 7%), the final
analytic sample was 1,403 participants (Table 1). Fifty-seven per-
cent of black women, 61% of Hispanics, and 69% of non-Hispanic
whites returned a completed questionnaire (P  .001). The re-
sponse rate did not differ by age.
Participant Characteristics and Factors Associated
With Receipt of Chemotherapy
Compared with non-Hispanic whites, black women and Hispan-
ics were more likely to have been diagnosed at a younger age
(P  .002) and to have stage II or III disease (P  .001), hormone
receptor–negative disease (P  .001), and higher-grade histology
(P  .001), as has been seen in our previous studies and the work of
other investigators.6-9,12,13,16-20,25,26 Black women and Hispanics were
also significantly more likely to have a household income less than
$20,000 and to have less than a high school degree than non-Hispanic
whites. In addition, black women were more likely than non-Hispanic
whites and Hispanics to have two or more comorbid conditions and to
be single. There was a nonsignificant difference in employment status
among racial/ethnic groups.
Chemotherapy receipt was reported by 293 black women (65%),
172 low-acculturated Hispanics (71%), 143 high-acculturated His-
panics (65%), and 462 non-Hispanic whites (57%; P  .001). In
multivariable analyses (Table 2), tumor characteristics (higher stage,
negative hormone receptor status, and higher tumor grade), younger
age (Fig 2), being Hispanic, and having insurance other than Medicaid
were associated with receipt of chemotherapy.
Original sample selected 
by the SEER registries
(N = 3,252) Excluded
   Physician refusal
   Patient too ill
   Reported never having 
      had cancer
   Non-English, non-Spanish 







   Could not be merged to 
      SEER registry
   Noninvasive cancer
   Missing chemotherapy data 
      from survey
   Race “other”
   Missing information for 
     any covariate, with the 
     exception of missing 









   Could not be located
   Located but did not 










Fig 1. Study sample flow diagram.
Table 1. Patient Demographic and Clinical Characteristics (n  1,403)
Characteristic No. %
Age group, years














ER and/or PR positive 1,050 75






 $20,000 246 18
$20,000 to $69,000 542 39








Not high school graduate 262 19
High school graduate 287 20
Some college 498 36
College graduate 356 25
Marital status




Not employed 577 41
Race/ethnicity
Black 361 26
Low-acculturated Hispanic 186 13
High-acculturated Hispanic 183 13
Non-Hispanic white 673 48
Abbreviations: ER, estrogen receptor; PR, progesterone receptor.
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Black women had an odds ratio (OR) of receiving chemother-
apy of 0.83 (95% CI, 0.64 to 1.08), a difference that is not signifi-
cant. Among Hispanics, low-acculturated Hispanics (OR, 2.00;
95% CI, 1.31 to 3.04) and high-acculturated Hispanics (OR, 1.43;
95% CI, 1.03 to 1.98) were both significantly more likely to receive
chemotherapy than non-Hispanic white women. The odds of re-
ceiving chemotherapy decreased with increasing age (OR, 0.91;
95% CI, 0.90 to 0.92). That is, each additional year of age had 0.91
odds of receipt of chemotherapy compared with the age preceding
it. Comorbidity, education, income, and marital status were not
independently associated with receipt of chemotherapy. No mean-
ingful interactions were identified in the fully interacted models,
and as described, interaction terms were not included in the mul-
tivariable analyses.
Patient-Reported Reasons for Not
Receiving Chemotherapy
Table 3 shows the reasons that patients reported for not re-
ceivingchemotherapy.Mostpatientsattributednonreceiptofchem-
otherapy to physician recommendation (74%) or lack of physician
discussion about chemotherapy (3%).68 Patient-related reasons
for not receiving chemotherapy included a preference not to re-
ceive chemotherapy when the physician left it to the patient to
make a decision (16%) and concerns about adverse effects or
complications (9%), desire to avoid hair loss (3%), cost concerns
(1%), and concern about chemotherapy being a burden to self or
family (3%). The reasons for omission of chemotherapy did not
differ by race/ethnicity.
DISCUSSION
In summary, in this large, diverse, population-based sample of
women diagnosed with breast cancer between 2005 and 2007, we
Table 2. Logistic Regression Modeling of Factors Associated With
Receipt of Chemotherapy (n  1,403)
Factor OR 95% CI P 
Age, years 0.91 0.90 to 0.93  .001
Comorbid conditions .547
None Referent
One 0.95 0.75 to 1.21
 Two 1.10 0.83 to 1.46
Stage  .001
I Referent
II 17.29 13.73 to 21.69
III 52.29 33.67 to 81.22
Hormone receptor status  .001
ER and/or PR positive Referent
ER negative/PR negative 3.34 2.51 to 4.44
Histologic grade  .001
1 Referent
2 2.91 2.24 to 3.78
3 4.39 3.27 to 5.88
Income .908
 $20,000 Referent
$20,000 to $69,000 0.94 0.67 to 1.31
 $70,000 0.97 0.65 to 1.46
Education .440
Not high school graduate Referent
High school graduate 0.78 0.52 to 1.18
Some college 1.17 0.77 to 1.77
College graduate 0.73 0.47 to 1.14
Insurance status  .001
Medicare Referent
Medicaid 0.59 0.37 to 0.95
Other 1.50 1.09 to 2.08
None 1.77 0.98 to 3.19
Marital status .246
Married/partnered Referent
Not married or partnered 1.15 0.91 to 1.45
Employment status .092
Employed Referent
Not employed 1.23 0.97 to 1.57
Race/ethnicity  .001
Non-Hispanic white Referent
Black 0.83 0.64 to 1.08
Low-acculturated Hispanic 2.10 1.28 to 3.44
High-acculturated Hispanic 1.28 0.89 to 1.85
NOTE. Model is adjusted for site (registry).
Abbreviations: ER, estrogen receptor; OR, odds ratio; PR, progester-
one receptor.


























< 30 30-39 40-49 50-59 60-69 70-79 ≥ 80
Fig 2. Percentage of patients receiving adjuvant chemotherapy by age category
adjusted for comorbidity, stage, hormone receptor status, grade, income, insurance,
education, marital status, employment status, registry (Detroit v Los Angeles), and
race/ethnicity.
Table 3. Patient-Reported Reasons for Not Receiving Chemotherapy (n  633)
Reason No. %
Physician related
My physician(s) said I did not need it 471 74
My physician(s) did not discuss it with me 18 3
Patient related
My physician(s) left it up to me and I chose not to 103 16
I was worried about side effects or complications 59 9
I did not want to lose my hair 18 3
I was worried about the cost 6 1
It would have been too much of a burden on me or my family 17 3
No reason selected 8 1
Respondents could select more than one reason.
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found no compelling evidence of adjuvant chemotherapy under-
use among black or Hispanic women regardless of level of accul-
turation. In fact, Hispanics had statistically significantly higher
odds of receiving chemotherapy than the other racial/ethnic
groups after controlling for measurable factors. Low-acculturated
Hispanics had the highest odds of receiving chemotherapy. These
findings were contrary to our hypotheses and may be related to the
types of facilities in which Hispanics receive specialty care. SES,
measured via education attainment and income, and marital status
were not associated with receipt of chemotherapy. With the excep-
tion of age and insurance, the only correlates of chemotherapy
receipt were disease characteristics associated with a higher risk of
distant recurrence and greater benefit of chemotherapy (higher
stage, higher grade, negative hormone receptor status). Most pa-
tients who did not receive chemotherapy attributed omission to
their physicians’ recommendations (or perhaps their perceptions
of physicians’ recommendations).
The relationship between increasing age and decreasing use of
chemotherapy (Fig 2) in our sample is consistent with previous
research.69-72 Despite the fact that older women with a life expectancy
of 5 or more years reap the same degree of risk reduction with chem-
otherapy as younger women,73,74 increasing age was an independent
factor associated with chemotherapy receipt. Rates of chemotherapy
receipt in our sample of older patients were higher than those in earlier
time periods,69,70 suggesting that dissemination regarding the benefits
of chemotherapy in otherwise healthy older patients is taking place.
There is, however, additional room for improvement in the care of
older women.75
The association between chemotherapy receipt and age among
women younger than age 50 years is particularly notable. Although
increasing age is associated with lower rates of chemotherapy receipt,
as described, age has not been shown to play a role in receipt of
chemotherapy in women younger than age 50 years. This novel find-
ing suggests that in our sample, age was incorporated into chemother-
apy decision making along the entire continuum of age. Unmeasured
tumor features, such as HER2 positivity and presence of angiolym-
phatic invasion, have been shown to be more common in younger
women in large, single-institution studies68,76 and may have been
more common in our participants younger than age 50 years com-
pared with older women. If present, such differences could account for
the higher rates of chemotherapy receipt in the younger women in
our sample.
The absence in our study of information on HER2 status and
angiolymphatic invasion limits the ability to explain not only rates of
chemotherapy among the younger patients but also the independent
association between Hispanic ethnicity and chemotherapy receipt.
HER2 status was not available in the SEER registries for patients in our
sample. Treatment guidelines in place at the time our patients were
diagnosed incorporated both HER2 status and the presence of angi-
olymphatic invasion (as a high-risk feature), and in fact, both features
have been shown to predict use of chemotherapy in women with
node-negative, estrogen receptor–positive disease.77 Higher rates of
angiolymphatic invasion or HER2-positive disease have been identi-
fied in some76 but not all18 studies that included Hispanics. There is no
evidence that HER2 status differs between black and non-Hispanic
white women.18,78
We also identified an association between insurance status and
chemotherapy receipt. Patients with insurance indicated as “other”
most likely had private insurance, and these patients had higher odds
of receiving chemotherapy compared with patients with Medicare;
Medicaid insurance was associated with chemotherapy omission, as
has been seen in other studies.47
In addition to lacking data on angiolymphatic invasion and
HER2 status, there are several other limitations of this study. We
did not have information on chemotherapy regimen, dose or dose-
intensity, or rates of completion of chemotherapy. Previous work
has shown that black women and women of lower SES are more
likely to receive nonstandard, often single-agent, chemotherapy
regimens79 and intentionally reduced doses of chemotherapy with
the first cycle of chemotherapy.80 Others have shown that black
women participating in clinical trials receive lower doses of chem-
otherapy over the course of their chemotherapy than white
women.81 Thus, although we have demonstrated no differences in
the rate of chemotherapy according to race/ethnicity, we cannot
state that the quality of chemotherapy is equivalent across different
patient subgroups.
Another limitation of this study is that our sample was drawn
from only two regions in the United States and included only patients
who speak English or Spanish, so we cannot necessarily generalize our
findings to other regions or other patient groups. Wu et al45 recently
demonstrated chemotherapy underuse according to area-level SES in
seven state registries, whereas our study did not demonstrate SES
disparities (using individual-level measures of SES). It is possible that
the two regions we included in our study differ from care in those
seven states in terms of urbanicity and availability of specialty cancer
services. Finally, response bias may be playing a role in that those who
participated in the study may differ in unmeasured ways from those
who did not participate in the study.
In conclusion, it seems that race and ethnicity need not pose
barriers to receipt of adjuvant chemotherapy. Such a finding is
encouraging as we continue to address racial and ethnic disparities
in the receipt of quality cancer care. Nonetheless, differences and
disparities do exist in receipt of chemotherapy according to age,
insurance, and employment status. These findings identify oppor-
tunities to continue to improve the quality of breast cancer care.
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